HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

6th Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 20-22, 2025 | Orlando, Florida, USA

GAB 2025

Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: a longitudinal study

Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Elizabeth Dale Gilley
The Elle Foundation, United States
Title : Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: a longitudinal study

Abstract:

The purpose of this editorial is to update the progress of Elle foundation case study 101, for whom a reward deficiency syndrome solution system (RDSSS) treatment plan was created in 2020, and her progress tracked daily during phase one in 2021. Analysis of phase one of this longitudinal study has been reported in more than one journal submission and published in peer review However, we have not yet reported the results of phase 2 or 3 in peer review.

The case study’s daily progress during each phase is tracked for 9 months, with three months off in between phases. Phase two was observed in year 2 of the study, which was 2022. Phase 3 was observed in year 3, 2023. Phase four is currently in progress, in 2024. In review, the RDS treatment plan developed by Blum’s group which was created for this participant began with genetic addiction risk severity (GARS) Screening. Test results found: 1) one risk allele (C/T), in the single nucleotide polymorphism DRD4; 2) 2 risk alleles in the variable tandem number repeats and insertions/deletions of the 5-HTT-Linked gene (S/S); and 3) risk alleles (4R/4R) of the variable tandem number repeats of MAOA 

The following tracks her remarkable progress in physiological, neurological, psychological social, and spiritual realms, attesting to the Reward Deficiency Syndrome Solution System, and the impact this has on individuals with complex mental disorders clusters.

Biography:

Elizabeth Dale Gilley earned a Bachelor of Science in Business Administration from Wake Forest University, in 1983, while lettering in Women’s Varsity Tennis. She also holds a paralegal degree in corporate law, with a bankruptcy specialty. After serving as Assistant to the Chairman her father, James Gilley, she left his tutelage to incorporate The Elle Foundation, in 1995, in Dallas, Texas. The original mission statement was to help stop the generational cycle of addiction.

After years of studying the financials of treatment centers and psychiatric hospitals, she established the Elle Foundation Award of Excellence, in 2000, to showcase innovation and novel contributions of those who are raising the bar above the 1950’s Minnesota Model industry standard. This award is still given today, not for the scientists or doctors, but for those who are still suffering to offer hope that solutions are forthcoming. 

She returned to academia in her 50’s earning a Masters in General Psychology (2017) and a Post Masters Specialty in Addictions from North Central University (2019), both with a GPA higher than Magna Cum Laude. She is presently a Ph.D candidate at National University, where her focus is upon the neuroscience and neurobiology of addiction. She has created psychological applications: therapy and psychoeducation for the new Reward Dysfunction Syndrome paradigm, and the RDS Severity of Symptom measurement tool, which may prove to be a behavioral marker for recovery and/or reinstatement. 

In 2004, she unincorporated the Elle Foundation, making it a private nonprofit, and considers it her personal altruism. She as created two new divisions, Elle Research and Elle Resource. While still conducting longitudinal research from the 100s series, Elle Research is developing its 200s series: Qualitative Exploratory Multiple Case Study to investigate the experiences of dually diagnosed patients, in the substance use disorder/ psychological/psychiatric industry which services one size fits all treatment, with pharmaceutical trial and error. The 200s series will also include quantitative study of the same participates to investigate the effectiveness of Psychiatric/Psychological Genomics, RDS solution focused brief therapy and the RDS SOS.

Elle Resource will deliver these therapeutic advancements to the public, both locally and internationally through teletherapy, focusing upon psychological genomics for patients with dopaminergic RDS mental health clusters. The Elle Foundation’s Dragon Slayer and Bridge Builder Ministry is reopening, in the fall of 2024, in Palm Beach Country to provide children’s and family services, introducing the new RDS paradigm, in a psychoeducation art therapy format.

She has published consistently in peer review for the past 7 years and has presented at the past 3 global conferences on addiction medicine, behavioral health and psychiatry. She also serves as a global conference scientific committee member. 

Watsapp